Medpace Hldgs (NASDAQ:MEDP) is preparing to release its quarterly earnings on Monday, 2026-02-09. Here’s a brief overview of what investors should keep in mind before the announcement.
Analysts expect Medpace Hldgs to report an earnings per share (EPS) of $4.21.
The announcement from Medpace Hldgs is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It’s worth noting for new investors that guidance can be a key determinant of stock price movements.
Historical Earnings Performance
In the previous earnings release, the company beat EPS by $0.32, leading to a 9.12% increase in the share price the following trading session.
Here’s a look at Medpace Hldgs’s past performance and the resulting price change:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | 3.54 | 2.99 | 3.08 | 3.12 |
| EPS Actual | 3.86 | 3.10 | 3.67 | 3.67 |
| Price Change % | 9.00 | 55.00 | -2.00 | -8.00 |
Tracking Medpace Hldgs’s Stock Performance
Shares of Medpace Hldgs were trading at $541.27 as of February 04. Over the last 52-week period, shares are up 52.68%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.
Analyst Views on Medpace Hldgs
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Medpace Hldgs.
A total of 2 analyst ratings have been received for Medpace Hldgs, with the consensus rating being Neutral. The average one-year price target stands at $562.5, suggesting a potential 0.17% upside.
Peer Ratings Overview
The following analysis focuses on the analyst ratings and average 1-year price targets of West Pharmaceutical Servs, Revvity and Icon, three prominent industry players, providing insights into their relative performance expectations and market positioning.
- Analysts currently favor an Neutral trajectory for West Pharmaceutical Servs, with an average 1-year price target of $302.5, suggesting a potential 46.13% downside.
- Analysts currently favor an Neutral trajectory for Revvity, with an average 1-year price target of $111.89, suggesting a potential 80.07% downside.
- Analysts currently favor an Neutral trajectory for Icon, with an average 1-year price target of $195.0, suggesting a potential 65.27% downside.
Key Findings: Peer Analysis Summary
In the peer analysis summary, key metrics for West Pharmaceutical Servs, Revvity and Icon are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.
| Company | Consensus | Revenue Growth | Gross Profit | Return on Equity |
|---|---|---|---|---|
| Medpace Hldgs | Neutral | 23.74% | $196.94M | 47.70% |
| West Pharmaceutical Servs | Neutral | 7.73% | $294.30M | 4.68% |
| Revvity | Neutral | 10.46% | $374.60M | 1.34% |
| Icon | Neutral | 0.63% | $554.45M | 0.02% |
Key Takeaway:
Medpace Hldgs ranks highest in Revenue Growth among its peers. It also leads in Gross Profit margin. However, it has the lowest Return on Equity. Overall, Medpace Hldgs is positioned well compared to its peers in terms of financial performance.
Unveiling the Story Behind Medpace Hldgs
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Financial Insights: Medpace Hldgs
Market Capitalization: Indicating a reduced size compared to industry averages, the company’s market capitalization poses unique challenges.
Revenue Growth: Medpace Hldgs displayed positive results in 3 months. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately 23.74%. This indicates a notable increase in the company’s top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Medpace Hldgs’s net margin is impressive, surpassing industry averages. With a net margin of 16.84%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company’s ROE is a standout performer, exceeding industry averages. With an impressive ROE of 47.7%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Medpace Hldgs’s ROA surpasses industry standards, highlighting the company’s exceptional financial performance. With an impressive 6.69% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Medpace Hldgs’s debt-to-equity ratio is below the industry average at 0.41, reflecting a lower dependency on debt financing and a more conservative financial approach.
To track all earnings releases for Medpace Hldgs visit their earnings calendar on our site.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
